F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.

Bares, Roland; Klever, P.; Hauptmann, S.; Hellwig, Dirk; Faß, J.; Cremerius, U.; Schumpèlick, V.; Mittermayer, Ch.; Büll, Ü.

doi:10.1148/radiology.192.1.8208970

Cited by 204 publications

(116 citation statements)

References 0 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Indeed, glucose competes with FDG for transport and a high level of plasma glucose could inhibit FDG uptake within the tumour. Bares suggested this competition to be a possib][e cause of false-negative results, but the four patients with false-negative findings reported by Stollfuss did not have diabetes or elevated glucose levels [163,168]. Evidence of metastatic extension of pancreatic carcinoma, lymph node involvement or liver metastases can be appreciated on PET images.…”

Section: Pancreatic Carcinomamentioning

confidence: 95%

“…Several groups, predominantly from Japan and Germany, have evaluated the role of FDG PET in the differentiation of pancreatic adenocarcinoma from benign chronic pancreatitis and mass-forming pancreatitis [163][164][165][166][167][168][169]. Results indicate a sensitivity of ca.…”

Section: Pancreatic Carcinomamentioning

confidence: 99%

“…Visual criteria use discrete focal elevated uptake as evidence for cancer, while diffuse or background level activity is taken as evidence for chronic pancreatitis or normal tissue. Bares et al [163] first commented on the importance of adequate blood glucose control for optimal FDG uptake by the tumour. Indeed, glucose competes with FDG for transport and a high level of plasma glucose could inhibit FDG uptake within the tumour.…”

Section: Pancreatic Carcinomamentioning

confidence: 99%

See 2 more Smart Citations

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

Section: Pancreatic Carcinomamentioning

confidence: 95%

Section: Pancreatic Carcinomamentioning

confidence: 99%

Section: Pancreatic Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

show abstract

“…We examined various blood tests which possibly influence the uptake of FDG, including blood sugar 27 and CRP 28 , in addition to ordinary blood tests of BUN, creatinine, bilirubin, ALP, amylase, WBC, and CA19-9.…”

Section: Laboratory Testsmentioning

confidence: 99%

Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography

et al. 2008

View full text Add to dashboard Cite

Purposes: Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer. Because autoimmune pancreatitis is easily misdiagnosed as pancreatic cancer and can be tested for by FDG-PET analysis based on the presence of suspected pancreatic cancer, we attempted to clarify the differences in FDG-PET findings between the two conditions. Methods: We compared the FDG-PET findings between 15 patients with autoimmune pancreatitis and 26 patients with pancreatic cancer. The findings were evaluated visually or semiquantitatively using the maximum standardized uptake value and the accumulation pattern of FDG. Results: FDG uptake was found in all 15 patients with autoimmune pancreatitis, whereas it was found in 19 of 26 patients (73.1%) with pancreatic cancer. The accumulation pattern of nodular shape was frequently seen in pancreatic cancer with significance, whereas a longitudinal shape indicated the existence of autoimmune pancreatitis. Heterogeneous accumulation was found in almost all cases of autoimmune pancreatitis, whereas homogeneous accumulation was found in pancreatic cancer. Most cases of pancreatic cancer showed solitary localization with significant difference, whereas multiple localizations in the pancreas favored the existence of autoimmune pancreatitis. FDG uptakes in the hilar lymph node were more frequently seen in autoimmune pancreatitis than in pancreatic cancer with significance, and those in the lachrymal gland, salivary gland, biliary duct, retroperitoneal space, and prostate were only seen in autoimmune pancreatitis. Conclusions: FDG-PET provides a useful tool for differentiating autoimmune pancreatitis from suspected pancreatic cancer, if its accumulation pattern and extra-pancreatic involvements are considered. IgG4 measurement and other current image tests will confirm further diagnosis.

show abstract

“…[7][8][9][10][11] Markedly increased FDG uptake in esophageal squamous cell carcinoma (SCC) has been documented in several studies, [12][13][14][15] and they have reported that PET using FDG shows greater sensitivity in the diagnosis of involved regional lymph nodes than computed tomography (CT). This suggests that PET may have a role in evaluating the stage of esophageal carcinoma.…”

mentioning

confidence: 99%

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Kato

Kuwano

Nakajima

et al. 2002

Cancer

275

View full text Add to dashboard Cite

show abstract

F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.

Abstract: FDG PET has the potential to improve the detection of lymphadenopathy and the differential diagnosis of pancreatic masses.

Cited by 204 publications

References 0 publications

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Contact Info

Product

Resources

About